Dr Johnson on Trastuzumab Plus Paclitaxel in HER2+ Breast Cancer
July 13th 2023Kai Conrad Cecil Johnson, MD, discusses key invasive disease-free survival findings from the final 10-year analysis of the phase 2 APT trial and HER2DX exploratory analyses in patients with HER2-positive breast cancer.
Read More